Lasa Supergenerics Ltd

Lasa Supergenerics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.7.13, marking a significant decline in its stock price amid ongoing market pressures and company-specific financial concerns.

Lasa Supergenerics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has recorded a new 52-week low of Rs.7.13 today, marking a significant decline in its stock price amid ongoing market pressures and company-specific factors.

Lasa Supergenerics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week and all-time low of Rs.7.29 today, marking a significant decline in its stock price amid ongoing market pressures and company-specific challenges.

Lasa Supergenerics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week and all-time low of Rs.7.59 today, marking a significant decline amid a broader market recovery. The stock has underperformed its sector and benchmark indices, reflecting ongoing financial pressures and subdued performance metrics.

Lasa Supergenerics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.7.7 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and operational metrics.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lasa Supergenerics Limited has reported catastrophic Q3 FY26 results that underscore the pharmaceutical manufacturer's accelerating operational crisis. The company posted a net loss of ₹2.55 crores for the quarter ended December 2025, representing a 59.20% improvement from the previous quarter's loss of ₹6.25 crores but a dramatic reversal from the ₹5.49 crores profit recorded in Q3 FY25. With a market capitalisation of just ₹44.00 crores and shares trading at ₹8.81, the stock has plunged 64.75% over the past year, reflecting investor capitulation as fundamental deterioration continues unabated.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 04 February 2026, providing investors with the latest insights into its performance and outlook.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 23 Jan 2026, hitting its lower circuit limit and registering a maximum daily loss of 2.55%. The stock’s sharp decline reflects mounting investor concerns amid deteriorating technical and fundamental indicators.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in buying interest on 22 Jan 2026, hitting its upper circuit price limit. Despite recent underperformance relative to its sector and broader market indices, the stock’s sudden rally underscores intense demand and a potential shift in investor sentiment.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 14 Jan 2026, hitting its lower circuit limit amid intense selling pressure. The stock closed at ₹9.43, down 4.46% on the day, marking its fifth consecutive day of losses and signalling mounting investor concerns.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 12 Jan 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The share price plunged by nearly 5%, marking its maximum daily loss and signalling panic selling among investors amid subdued market sentiment.

Lasa Supergenerics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 9 Jan 2026, hitting its lower circuit limit and registering a maximum daily loss of 4.8%. The stock’s sharp decline reflects mounting investor concerns amid falling participation and unfilled supply, signalling a period of heightened volatility and bearish sentiment.

Lasa Supergenerics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 February 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 07 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.